Compare WLY & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLY | VCEL |
|---|---|---|
| Founded | 1807 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Books | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 1994 | 1996 |
| Metric | WLY | VCEL |
|---|---|---|
| Price | $52.67 | $39.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $59.71 |
| AVG Volume (30 Days) | 408.9K | ★ 511.9K |
| Earning Date | 12-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ 171.90 | 60.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,796,103,000.00 | $276,259,000.00 |
| Revenue This Year | $4.68 | $21.71 |
| Revenue Next Year | $3.13 | $16.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 4.51 | ★ 16.45 |
| 52 Week Low | $28.38 | $28.95 |
| 52 Week High | $57.45 | $49.32 |
| Indicator | WLY | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 61.34 | 48.55 |
| Support Level | $48.69 | $37.78 |
| Resistance Level | $53.24 | $41.21 |
| Average True Range (ATR) | 1.41 | 1.29 |
| MACD | 0.59 | 0.13 |
| Stochastic Oscillator | 77.99 | 47.50 |
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning, which includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.